‘Disgraceful': The $3.8 billion renovation Trump wants to use to oust an old enemy
An attempt to remove Powell from his job before his term ends in May 2026 would undercut the Fed's long-standing independence from day-to-day politics and could lead to higher inflation, higher interest rates and a weaker economy.
The Supreme Court recently signalled that the president can't fire Powell simply because Trump disagrees with him on interest rates. But legally he could do so 'for cause,' such as misconduct or dereliction of duty.
Trump's workaround appears to be that Powell misrepresented the renovation project in congressional testimony and that the cost is excessive, thus meriting his dismissal.
The Fed's main headquarters is over 90 years old
The Fed says its main headquarters, known as the Marriner S. Eccles building, was in dire need of an upgrade because its electrical, plumbing and HVAC systems, among others, are nearly obsolete and some date back to the building's construction in the 1930s.
The renovation will also remove asbestos, lead and other hazardous elements and update the building with modern electrical and communications systems. The H-shaped building, named after a former Fed chair in the 1930s and '40s, is located near some of Washington's highest-profile monuments and has references to classical architecture and marble in the facades and stonework. The central bank is also renovating a building next door that it acquired in 2018.
The Fed says there has been periodic maintenance to the structures but adds that this is the first 'comprehensive renovation.'
The renovation costs have ballooned over the years
Trump administration officials have criticised the Fed over the project's expense, which has reached $US2.5 billion, about $US600 million more than was originally budgeted.
Loading
Like a beleaguered homeowner facing spiralling costs for a remodelling project, the Fed cites many reasons for the greater expense. Construction costs, including for materials and labor, rose sharply during the inflation spike in 2021 and 2022. More asbestos needed to be removed than expected. Washington's local restrictions on building heights forced it to build underground, which is pricier.
In 2024, the Fed's board cancelled its planned renovations of a third building because of rising costs.
The Fed says the renovations will reduce costs 'over time' because it will be able to consolidate its roughly 3000 Washington-based employees into fewer buildings and will no longer need to rent as much extra space as it does now.
White House budget director calls renovations 'ostentatious'
Russ Vought, the administration's top budget adviser, wrote Powell a letter last Thursday that said Trump is 'extremely troubled' about the Fed's 'ostentatious overhaul' of its facilities.
The Fed's renovation plans call for 'rooftop terrace gardens, VIP private dining rooms and elevators, water features, premium marble, and much more,' Vought said in his letter.
Powell has disputed the claims, which were given wide circulation in a paper issued by the Mercatus Center, a think tank at George Mason University, in March 2025. The paper was written by Andrew Levin, an economist at Dartmouth College and former Fed staffer.
'There's no VIP dining room,' Powell said last month during a Senate Banking Committee hearing. 'There's no new marble. ... There are no special elevators. There are no new water features. ... And there's no roof terrace gardens.'
Some of those elements were removed from initial building plans submitted in 2021, the Fed says.
But the White House also takes issue with the Fed reducing its renovation costs
The Fed's changes to its building plans have opened it up to another line of attack: White House officials suggest the Fed violated the terms of the approval it received from a local planning commission by changing its plans.
In its September 2021 approval of the project, the National Capital Planning Commission said it 'Commends' the Fed for 'fully engaging partner federal agencies.' But because the Fed changed its plans, the administration is indicating it needed to go back to the commission for a separate approval.
Essentially, White House officials are saying Powell is being reckless with taxpayer money because of the cost of the renovation, but they are also accusing him of acting unethically by scaling back the project to save money.
Loading
James Blair, the White House deputy chief of staff whom Trump named to the commission, said last Thursday in a post on X that Powell's June congressional testimony 'leads me to conclude the project is not in alignment with plans submitted to & approved by the National Capital Planning Commission in 2021.'
Speaking last Thursday at the planning commission meeting, Blair said he intends to tour the construction site, review materials from the Fed on how the approved 2021 renovation plans have changed and circulate a letter among his colleagues on the commission that would go to Fed officials.
The Fed has asked for an independent review of the project.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles

Sydney Morning Herald
27 minutes ago
- Sydney Morning Herald
Inside the decades-long friendship between Trump and Hulk Hogan
Washington: One was a businessman turned reality TV star who was twice-elected president. The other was a professional wrestler who became politically active later in life. Donald Trump and Hulk Hogan's paths first crossed at a wrestling event in the late 1980s at one of Trump's Atlantic City, New Jersey, hotels. The meeting kicked off a more than three-decade long friendship, marked by their career parallels: both were '80s celebrities who found greater fame in the world of reality television before wielding their influence in politics. Just over a year before his death on Thursday, Hogan delivered a rousing speech at the Republican National Convention in July 2024 in Milwaukee during which he dramatically ripped off his T-shirt — to reveal another one bearing the Trump-Vance campaign logo — and endorsed his 'hero,' Trump. Hogan said he was motivated by the attempted assassination of Trump days earlier in Butler, Pennsylvania. 'What happened last week, when they took a shot at my hero, and they tried to kill the next president of the United States, enough was enough, and I said: 'Let Trumpamania run wild brother. Let Trumpamania rule again, let Trumpamania make America great again,' Hogan said. On Thursday, Trump mourned his 'strong, tough, smart' friend, who died of a heart attack in Clearwater, Florida. He was 71. 'We lost a great friend today, the 'Hulkster.' Hulk Hogan was MAGA all the way — Strong, tough, smart, but with the biggest heart,' Trump wrote on his social media site, using the acronym for his 'Make America Great Again' campaign slogan. 'He gave an absolutely electric speech at the Republican National Convention, that was one of the highlights of the entire week,' Trump said. 'He entertained fans from all over the World, and the cultural impact he had was massive.'

Sydney Morning Herald
27 minutes ago
- Sydney Morning Herald
NeuroScientific appoints top doctor ahead of stem cell therapy rollout
Perth-based biotech NeuroScientific Biopharmaceuticals' clinical arsenal has just got a heavy-hitting upgrade with the appointment of well-credentialled Perth-based paediatric haematologist and oncologist Dr Catherine Cole as its chief medical officer. The hire has come at a critical time as the company accelerates the development of its recently acquired StemSmart technology. StemSmart uses a specific type of stem cell, mesenchymal stromal stem cells (MSC), as a last-line infusion treatment for critically ill patients, including those experiencing severe immune complications from bone marrow transplants, kidney and lung transplant rejection and the inflammatory Crohn's disease. The company expects later this year to receive the interim results from its latest compassionate trial involving patients with difficult-to-treat fistulising Crohn's disease, in which an open wound develops from a gut flare-up that extends out to the skin. A successful trial will help the company validate its proprietary StemSmart technology in this patient group, who otherwise have limited treatment options. 'Cathy's vast experience and leadership will greatly strengthen our management team.' Neuroscientific Biopharmaceuticals chairman Rob McKenzie Cole brings extensive experience to the table, having held clinical and academic leadership roles across Australia and overseas, including head of haematology and oncology at Perth Children's Hospital and professor of paediatric haematology and oncology at The University of Western Australia. She is also director of stem cell transplantation at Perth Children's Hospital, placing her front and centre in NeuroScientific's race to employ stem cell therapy to treat some of the most debilitating transplant complications and autoimmune diseases. The seasoned physician has additionally served on ethics committees and worked closely with national and international regulators, a skillset the company hopes will prove instrumental as it seeks regulatory approvals for StemSmart in Australia and abroad. NeuroScientific Biopharmaceuticals chairman Rob McKenzie said: ' We are very fortunate that Cathy is joining at this key time in the company's evolution. Her vast experience and leadership will greatly strengthen our management team as we progress our SAS fistulas in Crohn's program and make plans for future growth.'

The Age
27 minutes ago
- The Age
NeuroScientific appoints top doctor ahead of stem cell therapy rollout
Perth-based biotech NeuroScientific Biopharmaceuticals' clinical arsenal has just got a heavy-hitting upgrade with the appointment of well-credentialled Perth-based paediatric haematologist and oncologist Dr Catherine Cole as its chief medical officer. The hire has come at a critical time as the company accelerates the development of its recently acquired StemSmart technology. StemSmart uses a specific type of stem cell, mesenchymal stromal stem cells (MSC), as a last-line infusion treatment for critically ill patients, including those experiencing severe immune complications from bone marrow transplants, kidney and lung transplant rejection and the inflammatory Crohn's disease. The company expects later this year to receive the interim results from its latest compassionate trial involving patients with difficult-to-treat fistulising Crohn's disease, in which an open wound develops from a gut flare-up that extends out to the skin. A successful trial will help the company validate its proprietary StemSmart technology in this patient group, who otherwise have limited treatment options. 'Cathy's vast experience and leadership will greatly strengthen our management team.' Neuroscientific Biopharmaceuticals chairman Rob McKenzie Cole brings extensive experience to the table, having held clinical and academic leadership roles across Australia and overseas, including head of haematology and oncology at Perth Children's Hospital and professor of paediatric haematology and oncology at The University of Western Australia. She is also director of stem cell transplantation at Perth Children's Hospital, placing her front and centre in NeuroScientific's race to employ stem cell therapy to treat some of the most debilitating transplant complications and autoimmune diseases. The seasoned physician has additionally served on ethics committees and worked closely with national and international regulators, a skillset the company hopes will prove instrumental as it seeks regulatory approvals for StemSmart in Australia and abroad. NeuroScientific Biopharmaceuticals chairman Rob McKenzie said: ' We are very fortunate that Cathy is joining at this key time in the company's evolution. Her vast experience and leadership will greatly strengthen our management team as we progress our SAS fistulas in Crohn's program and make plans for future growth.'